Full Text
Diabetes mellitus has become one of the fastest-growing chronic diseases worldwide and represents a major contributor to global morbidity and mortality. Among its long-term complications, diabetic nephropathy is particularly important because it progressively impairs renal function and substantially increases the risk of cardiovascular disease, hospitalization, and premature death. Diabetic nephropathy accounts for a large proportion of patients receiving dialysis and kidney transplantation in both developed and developing countries.
Diabetic nephropathy develops gradually through a combination of metabolic, inflammatory, hemodynamic, and genetic mechanisms. Persistent hyperglycemia initiates complex biochemical pathways that promote oxidative stress, endothelial dysfunction, chronic inflammation, activation of the renin–angiotensin–aldosterone system, and accumulation of advanced glycation end products. These pathological processes progressively damage glomerular capillaries, mesangial cells, podocytes, and renal tubules, ultimately leading to irreversible nephron loss.
The earliest clinical manifestation of diabetic nephropathy is often moderately increased albumin excretion, reflecting disruption of the glomerular filtration barrier. Without appropriate intervention, persistent albuminuria progresses to overt proteinuria, declining glomerular filtration rate, hypertension, and chronic kidney disease. As renal function deteriorates, disturbances in electrolyte balance, acid-base homeostasis, erythropoietin production, mineral metabolism, and toxin elimination become increasingly evident.
The progression of diabetic nephropathy is influenced by numerous clinical factors. Poor glycemic control, uncontrolled hypertension, obesity, dyslipidemia, smoking, prolonged duration of diabetes, recurrent acute kidney injury, and genetic susceptibility all contribute to accelerated renal decline. Cardiovascular disease frequently coexists with diabetic nephropathy, creating a complex clinical syndrome characterized by mutually reinforcing cardiac and renal dysfunction.
Modern diagnosis relies on routine measurement of urinary albumin excretion together with estimation of glomerular filtration rate. Serial assessment of these parameters enables early recognition of renal injury before advanced structural damage becomes clinically apparent. Additional laboratory investigations, renal ultrasonography, and selected biomarkers contribute to comprehensive evaluation of disease severity and prognosis.
Therapeutic management has evolved considerably during the past decade. Intensive glycemic control, optimization of blood pressure, inhibition of the renin–angiotensin–aldosterone system, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, individualized nutritional therapy, and lifestyle modification have substantially improved renal and cardiovascular outcomes. These interventions slow disease progression by reducing intraglomerular pressure, suppressing inflammation, limiting fibrosis, and improving metabolic regulation.
Despite advances in pharmacological therapy, some patients inevitably progress to end-stage kidney disease. At this stage, renal replacement therapy becomes necessary to maintain life. Hemodialysis remains the most widely used renal replacement modality and effectively removes uremic toxins, corrects electrolyte disturbances, restores acid-base balance, and removes excess body fluid. Determining the optimal timing for initiation of hemodialysis is a critical clinical decision requiring careful assessment of symptoms, biochemical abnormalities, nutritional status, and residual renal function.
Rather than relying solely on estimated glomerular filtration rate, contemporary clinical practice emphasizes individualized assessment. Persistent uremic manifestations, refractory hyperkalemia, severe metabolic acidosis, fluid overload resistant to medical therapy, progressive malnutrition, and symptomatic decline in quality of life represent major indications for commencing dialysis. Early recognition of these complications reduces morbidity and improves long-term patient outcomes.
The present study aimed to evaluate modern approaches to the diagnosis and treatment of diabetic nephropathy while examining current clinical indications for hemodialysis and factors influencing disease progression and patient prognosis.
2. Materials and Methods
This prospective observational study was carried out between January 2023 and May 2025 at specialized nephrology and endocrinology departments of tertiary medical centers. The purpose of the investigation was to evaluate the clinical course of diabetic nephropathy, identify factors associated with disease progression, assess the effectiveness of contemporary therapeutic strategies, and determine evidence-based indications for the initiation of hemodialysis.
A total of 248 adult patients with confirmed diabetic nephropathy were enrolled in the study. Diagnosis was established according to internationally accepted nephrology guidelines based on persistent albuminuria, progressive decline in estimated glomerular filtration rate (eGFR), history of diabetes mellitus, laboratory investigations, and renal imaging findings. When clinically indicated, additional diagnostic procedures were performed to exclude alternative causes of chronic kidney disease.
Patients were stratified into three clinical groups according to renal function. Group I included patients with early diabetic nephropathy characterized by preserved or mildly reduced renal function. Group II consisted of individuals with moderate chronic kidney disease, while Group III included patients with advanced diabetic nephropathy approaching end-stage kidney disease. A subgroup of patients undergoing maintenance hemodialysis was analyzed separately to evaluate clinical outcomes after renal replacement therapy.
Comprehensive clinical assessment included demographic characteristics, duration and type of diabetes mellitus, body mass index, blood pressure, smoking status, cardiovascular history, diabetic retinopathy, diabetic neuropathy, medication adherence, nutritional status, and previous episodes of acute kidney injury.
Laboratory evaluation comprised fasting plasma glucose, glycated hemoglobin (HbA1c), serum creatinine, blood urea nitrogen, cystatin C, serum electrolytes, bicarbonate, complete blood count, serum albumin, lipid profile, calcium, phosphorus, parathyroid hormone, ferritin, transferrin saturation, C-reactive protein, and urinary albumin-to-creatinine ratio. Estimated glomerular filtration rate was calculated using validated international equations and monitored throughout follow-up.
Renal ultrasonography was performed in all participants to evaluate kidney size, cortical thickness, corticomedullary differentiation, renal echogenicity, and structural abnormalities. Doppler ultrasonography was additionally utilized in selected cases to assess renal vascular perfusion.
Cardiovascular assessment included electrocardiography, transthoracic echocardiography, and ambulatory blood pressure monitoring when clinically appropriate. These investigations allowed identification of left ventricular hypertrophy, systolic dysfunction, ischemic heart disease, and other cardiovascular complications commonly associated with advanced diabetic kidney disease.
All patients received individualized treatment according to current clinical recommendations. Therapeutic management included optimization of glycemic control, strict blood pressure regulation, renin–angiotensin–aldosterone system blockade, sodium-glucose cotransporter-2 inhibitors where indicated, glucagon-like peptide-1 receptor agonists, lipid-lowering therapy, correction of anemia and mineral metabolism disorders, dietary counseling, sodium restriction, individualized protein intake, smoking cessation, and regular physical activity.
Patients with advanced chronic kidney disease underwent repeated clinical evaluation to determine the appropriate timing for renal replacement therapy. Indications for initiation of hemodialysis included refractory hyperkalemia, severe metabolic acidosis, symptomatic uremia, uncontrolled fluid overload, progressive deterioration of renal function accompanied by clinical symptoms, severe malnutrition attributable to uremia, and persistently reduced estimated glomerular filtration rate together with declining clinical condition.
Clinical analysis demonstrated that deterioration of renal function closely correlated with duration of diabetes mellitus and long-term metabolic control. Patients with diabetes duration exceeding ten years exhibited significantly lower estimated glomerular filtration rates, higher urinary albumin excretion, and greater prevalence of hypertension than individuals with shorter disease duration.
Persistent hyperglycemia represented one of the strongest determinants of progressive nephron loss. Participants with elevated glycated hemoglobin values experienced more rapid decline in renal function, accelerated progression from microalbuminuria to overt proteinuria, and earlier development of advanced chronic kidney disease.
Hypertension was identified in the majority of patients with moderate and advanced diabetic nephropathy. Individuals with inadequately controlled blood pressure demonstrated significantly faster reduction in renal filtration capacity and increased cardiovascular morbidity compared with patients achieving recommended blood pressure targets.
Laboratory investigations revealed progressive elevation of serum creatinine, blood urea nitrogen, phosphorus, and parathyroid hormone concentrations with advancing disease stage. Simultaneously, hemoglobin concentration, serum albumin, and bicarbonate levels gradually declined, reflecting worsening renal insufficiency, chronic inflammation, metabolic acidosis, and impaired nutritional status.
Renal ultrasonography demonstrated increased cortical echogenicity, reduction of cortical thickness, and loss of corticomedullary differentiation in advanced diabetic nephropathy. These imaging abnormalities closely paralleled biochemical indicators of declining renal function.
Cardiovascular complications became increasingly prevalent as kidney disease progressed. Left ventricular hypertrophy, chronic heart failure, ischemic heart disease, peripheral vascular disease, and cerebrovascular disorders occurred significantly more frequently among patients with advanced nephropathy, emphasizing the close relationship between renal dysfunction and cardiovascular risk.
Despite comprehensive pharmacological management, a proportion of patients progressed to end-stage kidney disease requiring renal replacement therapy. Clinical indications leading to initiation of hemodialysis included persistent nausea, vomiting, anorexia, severe fatigue, generalized pruritus, cognitive impairment, refractory hyperkalemia, pulmonary edema caused by fluid overload, severe metabolic acidosis resistant to medical therapy, and symptomatic uremia.
Following initiation of maintenance hemodialysis, most patients demonstrated substantial improvement in biochemical parameters. Serum potassium, urea, creatinine, and acid-base balance improved significantly after regular dialysis sessions. Clinical symptoms including fatigue, dyspnea, anorexia, nausea, and peripheral edema also decreased markedly, resulting in improved functional status and quality of life.
Patients receiving multidisciplinary management involving nephrologists, endocrinologists, cardiologists, nutrition specialists, and dialysis teams demonstrated better clinical stability, fewer hospital admissions, and improved treatment adherence compared with patients receiving fragmented medical care.
The present study confirms that diabetic nephropathy remains the leading cause of end-stage kidney disease and represents one of the most challenging chronic complications of diabetes mellitus. Progressive renal injury results from continuous interaction between metabolic abnormalities, glomerular hypertension, inflammatory activation, oxidative stress, endothelial dysfunction, and tubulointerstitial fibrosis.
One of the principal observations of this investigation is the central importance of early diagnosis. Detection of microalbuminuria before substantial decline in glomerular filtration rate provides a valuable opportunity for timely intervention capable of delaying irreversible structural renal damage.
Strict glycemic control remains fundamental for preventing progression of diabetic nephropathy. Chronic hyperglycemia promotes formation of advanced glycation end products, activation of inflammatory signaling pathways, and excessive oxidative stress, all of which accelerate destruction of renal microvasculature. Maintaining individualized glycemic targets significantly slows deterioration of kidney function.
Blood pressure management constitutes another essential component of nephroprotective therapy. Persistent hypertension increases intraglomerular pressure, aggravates proteinuria, and accelerates nephron loss. Combined use of renin–angiotensin–aldosterone system inhibitors and contemporary antihypertensive therapy effectively reduces progression of chronic kidney disease.
Recent therapeutic advances, particularly sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, have transformed management of diabetic kidney disease. Beyond improving glucose control, these medications reduce albuminuria, preserve renal filtration capacity, decrease cardiovascular events, and delay progression toward dialysis-dependent renal failure.
Hemodialysis remains the principal renal replacement therapy for patients with advanced diabetic nephropathy who develop symptomatic uremia or severe metabolic complications. Contemporary practice emphasizes initiation based on overall clinical condition rather than estimated glomerular filtration rate alone. Early recognition of symptomatic renal failure allows timely dialysis initiation, minimizing life-threatening complications and improving patient outcomes.
Future research should focus on identification of novel molecular biomarkers capable of detecting diabetic nephropathy during its earliest reversible stages. Precision medicine, genomic profiling, artificial intelligence-assisted risk prediction, and regenerative therapeutic approaches may further improve individualized management and delay progression to end-stage kidney disease.
Diabetic nephropathy is the most common cause of chronic kidney disease and end-stage renal failure worldwide. Persistent hyperglycemia, uncontrolled hypertension, chronic inflammation, and oxidative stress collectively accelerate progressive renal damage and substantially increase cardiovascular morbidity and mortality.
Routine screening using urinary albumin excretion and estimated glomerular filtration rate enables early diagnosis before irreversible nephron loss occurs. Comprehensive management combining intensive glycemic control, strict blood pressure regulation, nephroprotective pharmacotherapy, nutritional intervention, and continuous clinical monitoring significantly delays disease progression.
Hemodialysis should be initiated according to clinical indications, including symptomatic uremia, refractory electrolyte disturbances, metabolic acidosis, fluid overload, and progressive deterioration of renal function despite optimal conservative treatment. A multidisciplinary patient-centered approach remains the most effective strategy for preserving residual kidney function, improving quality of life, reducing complications, and enhancing long-term survival in patients with diabetic nephropathy.
[1] Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(Suppl 4):S1–S150.
[2] Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5 Suppl):S1–S127.
[3] American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1–S350.
[4] de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the ADA and KDIGO. Diabetes Care. 2022;45(12):3075–3090.
[5] Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
[6] Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883.
[7] Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018.
[8] Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
[9] Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE Trial). N Engl J Med. 2019;380(24):2295–2306.
[10] Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229.
[11] Levin A, Stevens PE, Bilous RW, et al. KDIGO Clinical Practice Guideline for CKD evaluation and management. Kidney Int. 2024;105(Suppl 4):S1–S150.
[12] National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–S164.
[13] National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD. Am J Kidney Dis. 2022;79(4 Suppl 1):S1–S127.
[14] International Society of Nephrology. Global Kidney Health Atlas. ISN; 2023.
[15] International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: IDF; 2024.
[16] World Health Organization. Diabetes Fact Sheet. Geneva: WHO; 2025.
[17] World Health Organization. Chronic Kidney Disease: Global Health Perspectives. Geneva: WHO; 2024.
[18] Brenner BM, Rector FC. Brenner and Rector's The Kidney. 12th ed. Elsevier; 2024.
[19] Med1.uz. Diabetik nefropatiya: etiologiyasi, diagnostikasi va davolash. Available from: https://med1.uz/articles/nefrologiya/diabetik-nefropatiya
[20] Med1.uz. Gemodializ: ko‘rsatmalar va zamonaviy imkoniyatlar. Available from: https://med1.uz/articles/nefrologiya/gemodializ
[21] Med1.uz. Surunkali buyrak kasalligi va diabet. Available from: https://med1.uz/articles/nefrologiya/surunkali-buyrak-kasalligi
[22] Med1.uz. Diabetik nefropatiyada laborator diagnostika. Available from: https://med1.uz/articles/laboratoriya/diabetik-nefropatiya
[23] Med1.uz. Buyrak yetishmovchiligida nefroprotektiv davolash. Available from: https://med1.uz/articles/nefrologiya/nefroproteksiya
[24] Med1.uz. Buyrak transplantatsiyasi va dializ usullari. Available from: https://med1.uz/articles/nefrologiya/transplantatsiya-dializ
[25] Med1.uz. Qandli diabetning buyrak asoratlari. Available from: https://med1.uz/articles/endokrinologiya/diabet-buyrak
[26] Med1.uz. Surunkali buyrak kasalligining profilaktikasi va monitoringi. Available from: https://med1.uz/articles/nefrologiya/profilaktika